HC Wainwright Issues Pessimistic Outlook for UTHR Earnings

Key Points

• HC Wainwright lowered its Q4 2026 EPS forecast for United Therapeutics to $6.44 from $6.94, while estimating FY2028 earnings at $37.53 per share.
• United Therapeutics beat quarterly earnings expectations, reporting $7.27 EPS versus the $6.86 consensus, but revenue of $783.3 million fell short of estimates and declined 1.9% year over year.
• Analyst sentiment remains positive overall, with an average “Moderate Buy” rating and a $646 price target, although several firms recently reduced their targets. Insiders have sold more than $252 million of stock over the past 90 days.

United Therapeutics Corporation (NASDAQ:UTHR - Free Report) - Equities research analysts at HC Wainwright reduced their Q4 2026 earnings estimates for shares of United Therapeutics in a report released on Thursday, August 6th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings of $6.44 per share for the quarter, down from their previous forecast of $6.94. The consensus estimate for United Therapeutics' current full-year earnings is $26.32 per share. HC Wainwright also issued estimates for United Therapeutics' FY2028 earnings at $37.53 EPS.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company's quarterly revenue was down 1.9% on a year-over-year basis. During the same period in the prior year, the business posted $6.41 EPS.

A number of other research firms also recently weighed in on UTHR. Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. Royal Bank Of Canada dropped their price objective on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. Bank of America cut their price objective on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a report on Friday, July 10th. JPMorgan Chase & Co. raised their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research note on Thursday, July 23rd. Finally, Weiss Ratings cut shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research note on Friday, July 31st. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $646.00.

United Therapeutics Stock Performance

UTHR opened at $501.27 on Friday. United Therapeutics has a 52-week low of $302.19 and a 52-week high of $609.35. The firm has a market capitalization of $21.50 billion, a PE ratio of 17.93, a PEG ratio of 1.73 and a beta of 0.59. The business's 50-day simple moving average is $536.95 and its 200 day simple moving average is $535.97.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently modified their holdings of the business. Torren Management LLC acquired a new stake in United Therapeutics in the 4th quarter worth about $26,000. Activest Wealth Management increased its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 56 shares during the period. Fiduciary Financial Advisors bought a new position in shares of United Therapeutics during the second quarter worth approximately $30,000. WealthCollab LLC raised its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 38 shares in the last quarter. Finally, Rakuten Securities Inc. boosted its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 46 shares during the period. Institutional investors own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $517.05, for a total transaction of $4,291,515.00. Following the completion of the sale, the executive vice president owned 45,172 shares in the company, valued at $23,356,182.60. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $515.03, for a total value of $4,892,785.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at $167,097,878.29. The trade was a 2.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 462,575 shares of company stock valued at $252,568,724 over the last 90 days. Company insiders own 8.60% of the company's stock.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source